214 related articles for article (PubMed ID: 35707463)
1. Therapeutic Potential of Targeting Periostin in the Treatment of Graves' Orbitopathy.
Jang SY; Kim J; Park JT; Liu CY; Korn BS; Kikkawa DO; Lee EJ; Yoon JS
Front Endocrinol (Lausanne); 2022; 13():900791. PubMed ID: 35707463
[TBL] [Abstract][Full Text] [Related]
2. Yes-Associated Protein Mediates the Transition from Inflammation to Fibrosis in Graves' Orbitopathy.
Ko J; Kim YJ; Choi SH; Lee CS; Yoon JS
Thyroid; 2023 Dec; 33(12):1465-1475. PubMed ID: 37800725
[No Abstract] [Full Text] [Related]
3. The Role of Adipsin, Complement Factor D, in the Pathogenesis of Graves' Orbitopathy.
Byeon HJ; Chae MK; Ko J; Lee EJ; Kikkawa DO; Jang SY; Yoon JS
Invest Ophthalmol Vis Sci; 2023 Aug; 64(11):13. PubMed ID: 37555734
[TBL] [Abstract][Full Text] [Related]
4. Potential Therapeutic Role of Bone Morphogenic Protein 7 (BMP7) in the Pathogenesis of Graves' Orbitopathy.
Kim BY; Choi SH; Kim JY; Ko J; Yook JI; Kim HS; Lee EJ; Kikkawa DO; Yoon JS
Invest Ophthalmol Vis Sci; 2022 Jun; 63(6):7. PubMed ID: 35671049
[TBL] [Abstract][Full Text] [Related]
5. PERK mediates oxidative stress and adipogenesis in Graves' orbitopathy pathogenesis.
Ko J; Kim JY; Kyoung Chae M; Jig Lee E; Sook Yoon J
J Mol Endocrinol; 2021 May; 66(4):313-323. PubMed ID: 33870911
[TBL] [Abstract][Full Text] [Related]
6. Role of Proprotein Convertase Subtilisin/Kexin Type 9 in the Pathogenesis of Graves' Orbitopathy in Orbital Fibroblasts.
Lee GE; Kim J; Lee JS; Ko J; Lee EJ; Yoon JS
Front Endocrinol (Lausanne); 2020; 11():607144. PubMed ID: 33488522
[TBL] [Abstract][Full Text] [Related]
7. Glycogen Synthase Kinase-3β Mediates Proinflammatory Cytokine Secretion and Adipogenesis in Orbital Fibroblasts from Patients with Graves' Orbitopathy.
Lee JS; Chae MK; Kikkawa DO; Lee EJ; Yoon JS
Invest Ophthalmol Vis Sci; 2020 Jul; 61(8):51. PubMed ID: 32735324
[TBL] [Abstract][Full Text] [Related]
8. Disulfiram Exerts Antiadipogenic, Anti-Inflammatory, and Antifibrotic Therapeutic Effects in an
Wang X; Yang S; Ye H; Chen J; Shi L; Feng L; Wang X; Zhang T; Chen R; Xiao W; Yang H
Thyroid; 2022 Mar; 32(3):294-305. PubMed ID: 34605662
[No Abstract] [Full Text] [Related]
9. Inhibitory Effect of Idelalisib, a Selective Phosphatidylinositol 3-Kinase δ Inhibitor, on Adipogenesis in an In Vitro Model of Graves' Orbitopathy.
Ko J; Kim JY; Lee EJ; Yoon JS
Invest Ophthalmol Vis Sci; 2018 Sep; 59(11):4477-4485. PubMed ID: 30193323
[TBL] [Abstract][Full Text] [Related]
10. Signal transducer and activator of transcription 3 as a potential therapeutic target for Graves' orbitopathy.
Ko J; Kim JY; Kim BR; Lee EJ; Kikkawa DO; Yoon JS
Mol Cell Endocrinol; 2021 Aug; 534():111363. PubMed ID: 34116129
[TBL] [Abstract][Full Text] [Related]
11. Effect of tanshinone IIA in an in vitro model of Graves' orbitopathy.
Rhiu S; Chae MK; Lee EJ; Lee JB; Yoon JS
Invest Ophthalmol Vis Sci; 2014 Aug; 55(9):5900-10. PubMed ID: 25159204
[TBL] [Abstract][Full Text] [Related]
12. Chemokine Expression during Adipogenesis and Inflammation in Orbital Fibroblasts from Patients with Graves' Orbitopathy.
Lee CE; Choi SH; Yoon JS
Korean J Ophthalmol; 2020 Jun; 34(3):192-202. PubMed ID: 32495527
[TBL] [Abstract][Full Text] [Related]
13. Role of binding immunoglobulin protein (BiP) in Graves' orbitopathy pathogenesis.
Ko J; Kim JY; Lee EJ; Yoon JS
J Mol Endocrinol; 2021 Jan; 66(1):71-81. PubMed ID: 33112798
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic effect of ibrutinib, a selective Bruton's tyrosine kinase inhibitor, in orbital fibroblasts from patients with Graves' orbitopathy.
Park HY; Chae MK; Ko J; Kikkawa DO; Jang SY; Yoon JS
PLoS One; 2022; 17(12):e0279060. PubMed ID: 36521376
[TBL] [Abstract][Full Text] [Related]
15. 4-Methylumbelliferone suppresses hyaluronan and adipogenesis in primary cultured orbital fibroblasts from Graves' orbitopathy.
Yoon Y; Chae MK; Lee EJ; Yoon JS
Graefes Arch Clin Exp Ophthalmol; 2020 May; 258(5):1095-1102. PubMed ID: 31900640
[TBL] [Abstract][Full Text] [Related]
16. Biguanides Metformin and Phenformin Generate Therapeutic Effects via AMP-Activated Protein Kinase/Extracellular-Regulated Kinase Pathways in an In Vitro Model of Graves' Orbitopathy.
Han YE; Hwang S; Kim JH; Byun JW; Yoon JS; Lee EJ
Thyroid; 2018 Apr; 28(4):528-536. PubMed ID: 29589999
[TBL] [Abstract][Full Text] [Related]
17. Protein tyrosine phosphatase 1B as a therapeutic target for Graves' orbitopathy in an in vitro model.
Byeon HJ; Kim JY; Ko J; Lee EJ; Don K; Yoon JS
PLoS One; 2020; 15(8):e0237015. PubMed ID: 32760098
[TBL] [Abstract][Full Text] [Related]
18. Human placenta-derived mesenchymal stem cells ameliorate orbital adipogenesis in female mice models of Graves' ophthalmopathy.
Park M; Banga JP; Kim GJ; Kim M; Lew H
Stem Cell Res Ther; 2019 Aug; 10(1):246. PubMed ID: 31399042
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic Effect of Guggulsterone in Primary Cultured Orbital Fibroblasts Obtained From Patients with Graves' Orbitopathy.
Kim BR; Kim J; Lee JE; Lee EJ; Yoon JS
Invest Ophthalmol Vis Sci; 2020 Mar; 61(3):39. PubMed ID: 32196098
[TBL] [Abstract][Full Text] [Related]
20. Phospholipase C-γ as a Potential Therapeutic Target for Graves' Orbitopathy.
Roh TH; Chae MK; Ko JS; Kikkawa DO; Jang SY; Yoon JS
Endocrinol Metab (Seoul); 2023 Dec; 38(6):739-749. PubMed ID: 37989267
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
